Environment Bill

Debate between Philip Dunne and John Redwood

Wednesday 20th October 2021 Commons Chamber

[John Redwood]

Is there a possible compromise? The Minister said that the regulator could set and enforce targets and extract penalties; would that be a way forward? Could we get the Minister to come up with some tough regulatory targets that fall short of the absolute guarantee of a legal statement?

[Philip Dunne]

There will be targets—there are water-quality targets in the Bill anyway—and the Minister referred to the guidance that she is on the point of finalising for the next pricing review period for Ofwat. My Committee, the Environmental Audit Committee, is currently conducting an inquiry into water quality, and we will make some recommendations to strengthen that guidance, so there are tools that can be used. That does not, though, get away from the fact that in my view there should be a primary legislative duty on water companies, to persuade them to treat this issue with sufficient seriousness.

People, including my hon. Friend the Member for Harwich and North Essex (Sir Bernard Jenkin), have quite reasonably asked what the proposal would cost. Last week, our Committee heard evidence from Thames Water, which is currently investing in the largest capital treatment-works programme in our lifetime. It is a £4.6 billion investment, the purpose of which is to take away 37 million tonnes of sewage, out of a total of 39 million tonnes spilt legally into the Thames by Thames Water. It will have a huge impact on the reduction of the amount of sewage that is legally spilt into the Thames. The cost will be an increase of £19 per household in the bills of Thames Water’s water-rates payers in London. That illustrates quite well that, although the costs of improving the network are going to be significant —possibly huge: the Minister gave a range that is even bigger than the amount the Government have spent to combat covid—it will take decades.

When we asked the Secretary of State about this issue last year, when he appeared before our Committee for a different inquiry, he acknowledged that we will not deal with the problem of exceptional spillages out of water-treatment plants until such a time as the drainage system completely separates surface water from foul water. There are something like 200,000 km of combined sewers underneath our streets and fields. While they are combined, it provides the opportunity for water-treatment plants to be overwhelmed by excessive rainfall. The Opposition spokesman, the hon. Member for Plymouth, Sutton and Devonport, made the point that it is meant to happen only on an exceptional basis, but it absolutely is happening routinely. We discovered that information after the Government put pressure on the water companies to introduce event-duration monitors, which they have now done across almost all the network. That is giving rise to the information that The Guardian is collating that shows that the completely unacceptable spillage of sewage into rivers is routine. It has to stop. That was the intention behind my private Member’s Bill and is the reason why I continue to talk about this subject ad nauseum. I am much looking forward to the day when this Bill receives Royal Assent and I can get on to other matters.

Growing Back Better Report

Debate between Philip Dunne and John Redwood

Thursday 25th February 2021 Commons Chamber

[Philip Dunne]

I am grateful for the welcome that the hon. Gentleman has just given. I am delighted to hear that those on the Labour Front Bench are keen on a national nature service. It was first recommended in a report that we did as a Committee two or three years ago, so I am glad that all parts of the House are catching up with our Committee in its recommendations. On the scale of the measures that are required, our Committee did not seek to quantify them, but we absolutely recognise that this is a multi-year, multibillion-pound effort required in order to achieve the net zero ambition. It will reach across all elements of society and the economy; minor measures will not move the dial.

[John Redwood (Wokingham) (Con) [V]]

I strongly support the green VAT cuts. Did the Committee examine the future of the petrol and diesel car industry, and especially the future of the diesel engine parts, with all the skilled staff and big assets, if the Government move to an early ban on these new vehicles?

[Philip Dunne]

I am grateful to my right hon. Friend for his question. The Committee is taking an interest in the impact of a transition from the current economy, with its carbon-intensive sectors, to a net zero economy. We are looking at our future programme and some of the impacts of green jobs, which we are in the middle of an inquiry on now, and we will be addressing specifically the point that he makes about the impact on the motor sector. In the future, we are interested in some of the impacts of moving from an internal combustion engine source of transport to electrified transport and what that might do across different transport sectors. We will be working with the Transport Committee to ensure that we do not duplicate efforts, but that we are able to look into those matters.

Health Service Medical Supplies (Costs) Bill

Debate between Philip Dunne and John Redwood

Ping Pong: House of Commons
Wednesday 15th March 2017 Commons Chamber

[Mr Dunne]

The short answer is yes, it is. That is set out in the NHS constitution. The measures considered by the NICE board today provide some additional flexibility for NHS England in its handling of negotiations with the drugs companies over the introduction of new technology.

Let me conclude on amendment 3 by saying that the Government strongly believe that it would have a negative impact on the Government’s ability to operate price controls, so I ask Members to disagree with it.

I will deal briefly with the other amendments. Lords amendments 1 and 2 and amendments 4 to 24 were made in the other place. They are all amendments that the Government brought forward, having worked constructively with parliamentarians on improving the Bill.

Amendments 1 and 2 relate to the remuneration for persons providing pharmaceutical services in England and Wales respectively. The amendments provide for new regulation-making powers in respect of special medicinal products. These are unlicensed medicines that can be manufactured or imported to meet a patient’s individual needs when no licensed product is available.

The unique nature of specials—the hon. Member for Central Ayrshire (Dr Whitford) mentioned them during our consideration in this place—and their manufacturing arrangements mean that we need to do more to ensure that the prices paid by the NHS represent value for money for all these products. These amendments would enable England and Wales to develop options that will secure improved value for money—for example, by using a quotes system that has been trialled in Scotland, but there are also other options. We will consult the community pharmacy representative body on how best to take this forward.

Amendments 4 to 7 introduce a consultation requirement on the Government with regards to medical supplies. Again, the hon. Member for Central Ayrshire helpfully pointed out that such a requirement was in place for medicines, but not for medical supplies. I thank her for engaging with me and my officials, which has helped to improve the Bill.

The Government have listened to concerns in the House of Lords and in this House about the Government’s power to control the prices of medical supplies. These amendments would ensure that the first order to control the price of any medical supply would be subject to the affirmative procedure, giving both Houses an opportunity to discuss that order.

Amendments 8 and 9 and 15 to 17 are amendments to the information powers in the Bill. Responding to concerns from industry about the potential burdens of the proposed information power, they introduce an additional hurdle for the Government to obtain information by requiring them to issue an information notice whenever they require companies to provide cost information related to individual products, which can be appealed by the company concerned.

[John Redwood (Wokingham) (Con)]

One problem in coming to a fair price for a new drug—we want to reward the company for its innovation, but without being ripped off—is knowing what kind of production run or demand there might be for it. Is there any way that the NHS could get better at forecasting what its volume might be, as that might drive the price down?

[Mr Dunne]

As ever, my right hon. Friend, who is a champion of market solutions to some of these tricky problems, lights on an important point. We need to be better at trying to predict the take-up of medicines. Of course, until a new medicine has been introduced, it is very difficult to assess that, because it requires clinicians to get behind the product and to choose to prescribe it. He is absolutely right that we need to look at the way in which we model in order to have a negotiation with the pharmaceutical company that ensures that we build in as good a volume as we are expecting to maximise our prospects of getting the best price.

Let me return to Lords amendments 8, 9 and 15 to 17. When the Government ask a company to provide straightforward information about prices and other transaction costs or overall costs, there is no need for an information notice. The rationale is that there could be a significant burden on companies to provide product-level cost information. Any such request should be made only in exceptional circumstances—for example, in order to set the price of an unbranded generic medicine, when the Government would need insight into the costs and profits associated with the specific product.